---
schema_version: "secwatch.filing_event.v1"
accession: "0001214659-25-015660"
form_type: "8-K"
ticker: "CSDX"
cik: "0001106861"
company_name: "CS DIAGNOSTICS CORP."
filed_at: "2025-10-31T23:59:59+00:00"
generated_at: "2026-05-17T01:03:25.816397+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# CS Diagnostics completes conversion of Preferred B shares to 112.7M common shares; affiliates now hold common stock

## Summary
- Conversion of all Series B Preferred Stock held by affiliates CS Interpharm and CS Diagnostics Pharma into 112,652,000 common shares.
- Consolidates capital structure for consolidated financial reporting for FY ending Dec 31, 2025.
- Affiliates' resales of converted shares remain subject to Rule 144 volume and manner-of-sale restrictions.
- Benefits cited: enhanced transparency, improved efficiency, stronger alignment with common shareholders.

## SEC filing metadata
- accession: 0001214659-25-015660
- form_type: 8-K
- ticker: CSDX
- cik: 0001106861
- company_name: CS DIAGNOSTICS CORP.
- filed_at: 2025-10-31T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1106861/000121465925015660/0001214659-25-015660-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1106861/000121465925015660/i10312518k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001214659-25-015660
- JSON: https://secwatch.observer/filing/0001214659-25-015660.json
- Plain text: https://secwatch.observer/filing/0001214659-25-015660.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.